March 4, 2020 11:05 AM ESTUpdated 11:44 AM

Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes

Amber Tong

Linaprazan didn’t make much of a mark at AstraZeneca. Despite showing promise in early-stage studies, the potassium competitive acid blocker, or PCA-B,

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes

Amber Tong

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Can re­for­mu­la­tion of an As­traZeneca castoff ri­val Takeda's new heart­burn drug? Here's a $26M bet on yes

Amber Tong

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival